Clinical Assessment of GW815SF Salmeterol/Fluticasone Propionate (HFA MDI) in Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-

Trial Profile

Clinical Assessment of GW815SF Salmeterol/Fluticasone Propionate (HFA MDI) in Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 11 Aug 2009 Actual patient number (40) added as reported by ClinicalTrials.gov.
    • 14 Jul 2008 Actual end date is now 1 Nov 2007 as reported by ClinicalTrials.gov.
    • 14 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top